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Abstract 
Objective: To determine the impact of pharmacist-provided discharge medication counseling on 30 and 90 day hospital readmissions 
and ED visits in patients admitted with COPD exacerbation. 
Methods: A hospital-wide improvement was initiated, where COPD patients received discharge medication counseling and follow up 
phone call by a pharmacist.  A pilot study was implemented, and data on readmission rates at 30- and 90-days were collected and 
compared to a hand-matched, retrospective control group that had not received discharge counseling by a pharmacist.  Differences 
in readmission rates were analyzed using Chi-squared tests. 
Results: A total of 28 patients received discharge counseling by the pharmacist and were compared to 28 retrospective patients.  
Differences in 30-day and 90-day readmission rates were not significant (p=1.000 and p=0.589, respectively).  After thirty days, 7 
(25%) intervention and 7 (25%) retrospective group patients had been readmitted.  After ninety days, 11 (39.3%) intervention and 13 
(46.4%) non-intervention patients had been readmitted.  Since a small cohort of patients received discharge counseling, the study did 
not meet power. 
Conclusions: Although not statistically significant, patients who received discharge medication counseling provided by a pharmacist 
had lower 90-day readmission rates post discharge.  As regulations are implemented that penalize hospitals for readmissions that 
occur within 30 days of discharge, it is imperative that health care systems develop new strategies aimed at reducing readmission 
rates.  Further studies that are adequately powered are needed to assess the impact pharmacists can have on readmission rates.  
 
 
Introduction 
Chronic obstructive pulmonary disease (COPD) is one of the 
leading causes of 30-day readmissions among Medicare 
beneficiaries.1   Hospital readmissions and emergency 
department (ED) visits constitute a significant healthcare 
expenditure that may be prevented.  In the United States, 
19.6% of Medicare beneficiaries are readmitted within 30 
days following discharge; approximately one-third (34%) are 
readmitted within 90 days.1  High readmission rates   
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contribute to rising healthcare costs, estimated at $17.4 
billion annually.1  COPD alone accounts for more than 1.5 
million ED visits and 725,000 hospitalizations annually, 
resulting in nearly $60 billion in healthcare costs.8  
 
Under Section 3025 of the Affordable Care (ACA), the 
Hospital Readmissions Reduction Program penalizes 
reimbursement for select diagnosis-related groups (DRGs) 
based on readmission rates.2  Beginning in fiscal year (FY) 
2013, the policy included DRGs for myocardial infarction, 
heart failure, and pneumonia.  With the start of FY 2015, this 
policy will expand to include total hip and total knee 
arthroplasty, percutaneous transluminal coronary 
angioplasty, and COPD.2  As these regulations are 
implemented and this policy expands, it is imperative that 
healthcare systems pursue new strategies to reduce 
readmission rates, particularly for COPD patients who have a 
30-day readmission rate of 22.6%.9,10 
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Some components of a discharge plan can be optimized to 
effectively reduce readmissions.  Including a nurse as a 
discharge advocate and a pharmacist to conduct follow-up 
phone interviews, significantly reduced 30-day hospital 
readmissions and ED visits.3   Likewise, a respiratory outreach 
program that included clinical nurse specialists and 
physiotherapists in the plan also significantly reduced 180-
day hospital and ED readmission rates.4  Other studies have 
also demonstrated significantly improved readmission rates 
after creating a protocol-driven discharge plan in both the 
general medical population and COPD patients.5-7  
 
For COPD patients, medication non-adherence is considered a 
significant contributing factor for readmissions.9,10  
Researchers evaluating the impact of discharge counseling 
have utilized nurses to provide medication education.3-6  
Although the nurses in these studies received training to 
provide medication counseling, the provision of information 
was limited to the education they received3-6 and, therefore, 
limited the comprehensiveness of the discharge counseling 
provided.  However, pharmacists are well-equipped to 
provide comprehensive medication counseling at discharge 
due to their extensive knowledge of medication therapy,11,12 
and a cost-effectiveness evaluation has shown pharmacist-led 
discharge counseling to provide cost-savings in 48% of 
scenarios.13   The impact on readmissions of pharmacist-
driven medication therapy management services at 
discharge, specifically for COPD exacerbations, has not been 
previously studied.  Such an intervention may significantly 
reduce readmissions and ED visits related to COPD 
exacerbations by improving patient education and 
adherence.12 
 
The aim of the present study is to determine the impact of 
pharmacist-provided discharge medication counseling on 
subsequent hospital readmissions and ED visits in patients 
admitted with COPD exacerbation.   
 
Methods 
Institutional Review Board (IRB) was obtained prior to 
beginning this study.   
 
Intervention 
A hospital-wide improvement was initiated with COPD 
patients at an urban community medical center during the 
weekdays.  Due to staffing constraints, patients typically did 
not receive discharge counseling on the weekends.  Each 
morning, a pharmacist would review the patients who were 
admitted to the hospital on the prior day for eligibility.  
Patients with a respiratory or cardiovascular condition-
related admission were further reviewed to determine if the 
patients met the inclusion/exclusion criteria for discharge 
counseling.  If eligible, patients were monitored for time of 
discharge and received discharge medication counseling.   
 
Patients were deemed eligible for discharge if noted in the 
electronic medical record (EMR) by hospital staff.  At that 
time, the pharmacist printed out the after visit summary 
(AVS) to determine the patient's new medications, which 
medications will be continued, and which medications the 
patient needs to stop taking upon discharge.  The pharmacist 
then provided discharge counseling on each medication, 
specifically focusing on respiratory medications.  For inhaled 
medications, the pharmacist utilized American College of 
Chest Physicians (CHEST) inhaler sheets for instruction.14  The 
patient also was given the "Your Discharge Planning 
Checklist"15 to assist with determining what questions they 
needed answered prior to discharge.  If the pharmacist 
identified an error or patient concern which needed 
addressed, the admitting physician was contacted and 
clarifications were made as necessary.  Finally, the pharmacist 
reviewed the importance of follow-up with the patient's 
primary care physician following discharge.   
 
Post-discharge, a pharmacist called each patient 3-5 days 
later to follow-up regarding his or her new medications and 
to determine whether the patient had any problems with the 
medication, including side effects or cost barriers.  The 
department tracked patients counseled in order to make sure 
follow-up occurred. 
 
Data Collection 
Data were collected for patients who received the hospital-
wide improvement discharge counseling from April 9, 2013 
through May 9, 2014 as a post-interventional pilot project 
through chart review.  Patient demographic information (age, 
gender, race/ethnicity, insurance status) as well as 
comorbidities, smoking status, complete medication list at 
admission and discharge, length of stay, whether or not 
follow-up occurred, and 30- and 90-day readmission rates 
were obtained.  For comparison, a group of patients were 
examined retrospectively.  The same data were gathered as 
the intervention group, with the exception of the follow-up 
phone call.  Records were examined for those patients with a 
primary or secondary diagnosis of COPD exacerbation from 
October 1, 2010 to September 30, 2012.  
 
 
 
Inclusion/Exclusion Criteria 
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Inclusion criteria for both groups were: 18-89 years of age; 
primary admission diagnosis of (1) COPD exacerbation or 
acute on chronic respiratory failure with a diagnosis of COPD 
or (2) secondary admission diagnosis of COPD exacerbation or 
acute on chronic respiratory failure with a diagnosis of COPD 
with a primary diagnosis of a related respiratory or 
cardiovascular condition (pneumonia, asthma, viral upper 
respiratory tract infection, heart failure exacerbation); 
discharged to the community setting (e.g., not an extended-
care facility); and English as a primary language.  Patients 
from the intervention were only included if they were able to 
be contacted for the post-discharge phone call. 
 
Exclusion criteria were: discharge to a long-term care facility 
or an extended-care facility, discharge or transfer to another 
hospital, subjects who were incarcerated, non-English 
speaking / English not as a primary language, inability to read 
and comprehend basic written English (as self-reported by 
patient), pregnancy, and physical or mental disability 
significant enough to prevent the patient from being able to 
directly participate in the majority of study interventions 
(based on the clinical judgment of the staff).  
 
Outcome Measures 
The primary outcome was readmission (ED visits and 
rehospitalizations) at 30 days.  The secondary outcome of the 
study was readmission (ED visits and rehospitalizations) at 90 
days.   
 
Statistical Analyses 
Descriptive statistics were calculated for patient 
characteristics and included frequencies and percentages for 
categorical variables and means and standard deviations for 
continuous variables. A total of 142 patients with COPD were 
assessed retrospectively.  Researchers hand-matched two 
sets of retrospective patients to the intervention patients, 
and differences between groups were assessed.  Differences 
in patient demographics between the retrospective COPD 
cohort (no discharge counseling) and the intervention group 
(received discharge counseling) were assessed using a 
Pearson Chi Square test or an unpaired t-test, as appropriate. 
One group had a significant difference in the number of COPD 
medication at discharge (p=0.001); thus, the retrospective 
group with no differences was utilized for analyses. 
Differences in readmission rates between the retrospective 
and the intervention groups were assessed using a Pearson 
Chi Square test.   
 
The associations of gender, age, ethnicity, smoking status, 
number of comorbidities, presence of hypertension diagnosis, 
presence of diabetes diagnosis, presence of congestive heart 
failure diagnosis, number of COPD medications prior to 
admission, number of maintenance (non-COPD) medications 
prior to admission, number of COPD medications at 
discharge, number of maintenance (non-COPD) medications 
at discharge, and whether patients were in the intervention 
or retrospective group with 30-day and 90-day hospital 
readmissions were explored with logistic regression analysis.   
 
An a priori level of 0.05 was used for statistical significance.  
All analyses were performed using IBM® SPSS v. 22.0 for 
Windows (Armonk, New York).   
 
Results 
A total of 28 patients from the retrospective review were 
successfully matched to the intervention group and utilized as 
the retrospective group.  Most retrospective group patients 
were female (67.9%) and current or former smokers (100%).  
At completion of the study period, 28 patients received the 
intervention.  Again, most were female and current/former 
smokers (see Table 1).  There were no statistically significant 
differences between the matched retrospective and 
intervention groups. There were statistically significant 
differences between the entire retrospective cohort and 
intervention groups in the following areas:  quantity of COPD 
medications prior to admission (p=0.013) and at discharge 
(p=0.045) as well as maintenance medications (p=0.033) prior 
to admission.  No other differences between the entire 
retrospective cohort and intervention groups were 
statistically significant. 
 
After 30 days (see Table 2), 7 (25%) intervention and 7 (25%) 
matched retrospective group patients had been readmitted.  
There was no significant difference between groups 
(p=1.000).  After 90 days, 11 (39.3%) intervention and 13 
(46.4%) matched retrospective patients had been readmitted.  
There was no significant difference between groups 
(p=0.589). Examining the full retrospective sample, 5 (17.9%) 
intervention and 46 (32.4%) retrospective group patients had 
been readmitted.  There was no significant difference 
between groups (p=0.125).  After ninety days, 13 (46.4%) 
intervention and 76 (53.5%) non-intervention patients had 
been readmitted.  There was no significant difference 
between groups (p=0.492). 
 
No variables were associated with 30-day readmissions when 
evaluated with a logistic regression (see Table 3).  Only two 
variables were associated with 90-day readmissions:  age and 
whether patients were in the prospective or retrospective 
group.  Patients who had experienced 90-day readmissions 
were likely to be younger (see Table 4) and in the 
retrospective group (see Table 2). 
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Discussion 
This small, pilot study assessed the association between 
pharmacist discharge medication counseling and readmission 
rates for patients with COPD in order to determine if this is an 
effective method of improving patient outcomes.  Results 
showed that when a pharmacist conducted the medication 
discharge counseling, readmission rates for the intervention 
group vs. the matched retrospective at 90 days decreased by 
7.1% and by 15.4% when compared to the entire 
retrospective group.  The differences were not statistically 
significant; according to post-hoc power analyses, as there 
was insufficient power to detect statistical differences (power 
= 31.1%).  Whether patients were in the retrospective or 
intervention group did increase the likelihood of 90 day 
readmission when examined using logistic regression.  Thus, 
further investigation is necessary regarding the impact of the 
pharmacist in discharge education.  The study results did 
show a statistically significant difference in the number of 
both COPD and maintenance medications between the entire 
retrospective cohort and intervention groups upon admission 
and discharge.  This highlights an opportunity for pharmacist 
interventions to positively impact patient medication 
education and adherence and potentially decrease hospital 
readmission rates.  
 
Other studies have shown similar outcomes with patient 
discharge counseling programs conducted by pharmacists, 
nurses, or other health professionals.4-6  Self-management 
discharge education in COPD patients16 and nurse-led 
discharge counseling with pharmacist follow-up in general 
medicine patients3 both have effectively reduced 
rehospitalizations.  Several studies have shown pharmacists 
to play significant roles in reducing medication-related 
readmissions by preventing adverse drug events.12,17  In a 
report by Wiggins et al., pharmacist interventions in patients 
with heart failure demonstrated improved patient 
knowledge, reductions in medication discrepancies and 
errors, fewer hospital readmissions, and lower costs.12  
Although small in nature, this study demonstrates the 
potential for discharge counseling conducted by a pharmacist 
to reduce the number of hospital readmissions in the COPD 
population.  
 
Medication non-adherence has been identified as a 
significant contributing factor for readmissions in both the 
general medical population1,11,12 and in patients hospitalized 
for COPD exacerbation.9,10  Data suggest that counseling 
patients before discharge reduces medication discrepancies 
and improves medication adherence.12  Of the previous 
studies conducting discharge medication counseling, most 
have utilized nurses to provide education to patients about 
their medications. 3-5,6  Although the nurses serving as 
discharge advocates and transition coaches were trained to 
provide medication counseling for the study, the scope of 
information they could provide to patients about their 
medications was limited.  Therefore, certain aspects of 
medication counseling, such as answering the patient’s 
questions or accounting for a patient’s specific needs relative 
to medication therapy, could be better addressed by a 
pharmacist, due to the nature and length of their education. 
 
Pharmacists are trained to counsel patients about their 
medications, detect and resolve discrepancies, and screen for 
nonadherence and adverse drug reactions.  Future studies 
should continue to examine the impact of pharmacist-led 
discharge counseling.  Utilizing pharmacists to conduct 
discharge counseling may also provide significant cost savings 
to hospitals.  A study by Chinthammit et al. used a cost-
effectiveness decision analytic model to evaluate the cost-
effectiveness of pharmacist discharge counseling on 
medication related morbidity in both the high-risk elderly and 
general US population.13  Discharge counseling conducted by 
a pharmacist detected 89% of all medication errors and 
provided cost-savings in 48% of scenarios, with the greatest 
benefits found in the high-risk elderly patients.13  Larger 
studies could determine the actual cost savings gained 
through pharmacist-led discharge counseling in the COPD 
population. 
 
Limitations 
There were several limitations to this study.  The study was 
conducted in a single-center, small, Midwestern hospital in an 
urban setting, serving predominately low socioeconomic 
status patients.  Results in this study population may not be 
generalizable to other populations.  Also, the intervention 
sample size was small and did not meet the power needed to 
assess the primary outcome measure.  Patients in the 
intervention group were only included if they could be 
contacted for the post-discharge phone call, limiting the 
sample size.  Larger, adequately powered studies are needed 
to examine whether pharmacist-led discharge counseling is 
effective in reducing 30- and 90-day readmission rates.  
Staffing issues prevented data collection on the weekends, 
when many patients were discharged, and during times of 
lower staffing, there were no pharmacists available for 
discharge counseling.  In order to implement pharmacist-
based discharge counseling, hospitals may have to commit 
additional staffing.  Future research should examine the cost-
effectiveness of such initiatives.  Lastly, researchers could not 
determine if patients were admitted to hospitals outside of 
the network, due to data limitations.  Thus, the number of 
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readmissions in the intervention and retrospective groups 
may have been underestimated.  Collaborative projects with 
all hospitals in a given area could be considered in future 
studies.  
 
Conclusion 
 It is important to improve 30-day readmission rates, 
specifically in patients with chronic disease states given the 
new ACA reimbursement policies.  COPD is the leading 
respiratory-related cause of death and also the most costly 
respiratory illness in the US.18 Furthermore, it is a leading 
cause of 30-day rehospitalizations among Medicare 
beneficiaries, second only to heart failure.1  As regulations are 
implemented that penalize hospitals for readmissions that 
occur within 30 days of discharge, it is imperative that health 
care systems develop new strategies aimed at reducing 
readmission rates.  Pharmacist-led discharge counseling may 
be an effective strategy to reduce readmission rates and 
control costs in the COPD population. 
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Table 1.  Demographic and Health-related Characteristics of Participants by 
Retrospective versus Intervention Group 
 
 Intervention compared 
to all retrospective 
Intervention compared to 
matched retrospective 
 Retrospective 
(N=142) 
Matched 
Retrospective  
(N=28) 
Intervention 
(N=28) 
Test Statistic p-value Test Statistic p-value 
Gender N(%)    1.95a 0.163 0.00a 1.000 
Male 66 (46.5) 9 (32.1) 9 (32.1)     
Female 
 
76 (53.5) 19 (67.9) 19 (67.9)     
Age, Mean(SD) 
 
66.17 (11.02) 63.6 (9.74) 64.0 (9.77) 0.97b 0.334 0.15b 0.881 
Ethnicity, N(%)    0.72a 0.699 2.99a 0.084 
Caucasian 123 (86.6) 27 (96.4) 23 (82.1)     
African American 18 (12.7) 1 (3.6) 5 (17.9)     
Arabic 
 
1 (0.7) 0 (0.0) 0 (0.0)     
Smoking Status, N(%)    1.50a 0.683 0.29a 0.589 
Former Smoker 56 (39.4) 11 (39.3) 13 (46.4)     
Current Smoker 80 (56.3) 17 (60.7) 15 (53.6)     
Never Smoked 
 
3 (2.1) 0 (0.0) 0 (0.0)     
Comorbidities, Mean(SD) 
 
5.27 (2.93) 4.0 (2.04) 5.0 (2.24) 0.52b 0.605 0.15b 0.097 
Diseases, N(%)        
Hypertension 97 (68.3) 15 (53.6) 13 (46.4) 5.12a 0.023 0.29a 0.593 
Diabetes Mellitus 50 (35.2) 9 (32.1) 9 (32.1) 0.11a 0.737 0.00a 1.000 
CHF 
 
39 (27.5) 7 (25.0) 7 (25.0) 0.08a 0.773 0.00a 1.000 
COPD medications prior to 
admission, Mean(SD) 
2.32 (1.81) 1.57 (1.48) 3.12 (1.40) -2.57b 0.013 4.00b <0.001 
Other maintenance 
medications prior to 
admission, Mean(SD) 
 
8.57 (5.09) 7.75 (4.84) 11.00 (5.35) -2.22b 0.033 2.38b 0.021 
COPD medications at 
discharge, Mean(SD) 
 
4.32 (1.89) 4.11 (1.91) 3.56 (1.25) 2.03b 0.045 -1.26b 0.213 
Other maintenance 
medications at discharge, 
Mean(SD) 
10.28 (5.01) 10.14 (5.17) 12.26 (5.51) -1.74b 0.091 1.47b 0.148 
a=Pearson Chi Square value; b=t-test t-value 
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Table 2.  Differences in Readmission Rates between the Retrospective and Intervention Groups 
 
    All Retrospective 
vs. Intervention 
Matched Retrospective 
vs. Intervention 
 All 
Retrospective 
N (%) 
Matched 
Retrospective 
N (%) 
Intervention 
N (%) 
Pearson 
Chi-Square 
Value 
p-
value 
Pearson Chi- 
Square Value 
p-
value 
30 day 
readmissions 
 
46 (32.4) 7 (25) 7 (25) 2.35 0.125 0.00 1.000 
90 day 
readmissions 
76 (53.5) 13 (46.4) 11 (39.2)  0.47 0.492 0.29 0.589 
All Retrospective N=142; Matched Retrospective N=28; Intervention N=28 
 
 
 
Table 3.  Association of Demographic and Health-Related Variables with  
30-Day and 90-Day Readmissions 
 
Patient Characteristic 30 day readmission 
B (95% CI) 
90 day 
readmission  
B (95% CI) 
Age 0.98 (0.95-1.02) 0.96 (0.93-0.996) 
Gender 1.26 (0.61-2.61) 0.69 (0.35-1.38) 
Race/Ethnicity 1.92 (0.78-4.75) 2.55 (0.96-6.81) 
Number of Comorbidities 1.16 (0.99-1.35) 1.05 (0.90-1.22) 
Hypertension Diagnosis 1.63 (0.71-3.77) 1.76 (0.79-3.92) 
Diabetes Diagnosis 1.23 (0.55-2.78) 0.97 (0.44-2.10) 
Heart Failure Diagnosis 0.82 (0.36-1.92) 0.75 (0.32-1.71) 
Number of COPD Medications Prior to Admission 1.25 (0.91-1.71) 1.25 (0.93-1.70) 
Number of Maintenance Medications Prior to Admission 1.03 (0.83-1.26) 1.04 (0.85-1.26) 
Number of COPD Medications at Discharge 0.90 (0.67-1.21) 0.97 (0.74-1.28) 
Number of Maintenance Medications at Discharge 1.03 (0.84-1.26) 1.02 (0.85-1.24) 
Retrospective or Intervention Group 2.22 (0.75-6.59) 3.64 (1.28-10.36) 
aBold-face entries denote significant differences (p<0.05) 
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Table 4.  Differences in Demographic and Health-related Characteristics of  
All Participants by 30- and 90-Readmissions 
 
 30 day Readmission 90 day Readmission 
 Yes  No  Test 
Statistic 
p-
value 
Yes No Test 
Statistic 
p-
value 
Gender N(%)   0.29a 0.620   0.68a 0.441 
Male 25 (33.3) 50 (66.7)   35 (47.3) 39 (52.7)   
Female 
 
28 (29.5) 67 (70.5)   51 (53.6) 44 (46.3)   
Age, Mean(SD) 
 
65.19 
(11.45) 
66.09 
(10.58) 
0.50b 0.615 64.44 
(11.12) 
67.21 
(10.48) 
1.66b 0.098 
Ethnicity, N(%)   3.09a 0.214   3.25a 0.197 
Caucasian 43 (29.4) 103 
(70.5) 
  70 (48.3) 75 (51.7)   
African American 9 (39.1) 14 (60.9)   15 (65.2) 8 (34.8)   
Arabic 
 
0 (0.0) 1 (100.0)   0 (0.0) 1 (100.0)   
Comorbidities, Mean(SD) 
 
5.91 
(2.93) 
4.91 
(2.73) 
-2.10b 0.038 5.37 
(2.98) 
5.05 
(2.68) 
-0.74b 0.459 
Diseases, N(%)         
Hypertension  33 (30.0) 77 (70.0) 0.09a 0.767 53 (48.6) 56 (51.4) 0.48a 0.521 
Diabetes Mellitus 20 (33.9) 39 (66.1) 0.42a 0.600 33 (56.9) 25 (43.1) 0.26a 0.153 
CHF 
 
18 (39.1) 28 (60.9) 2.074a 0.190 26 (56.5) 20 (43.5) 0.890a 0.389 
COPD medications prior to 
admission, Mean(SD) 
 
2.87 
(1.83) 
2.27 
(1.71) 
-2.08b 0.039 2.77 
(1.85) 
2.10 
(1.61) 
-2.51b 0.013 
Other maintenance medications 
prior to admission, Mean(SD) 
 
10.38 
(5.27) 
8.33 
(5.05) 
-2.41b 0.017 9.76 
(5.36) 
8.05 
(4.82) 
-2.17b 0.031 
COPD medications at discharge, 
Mean(SD) 
 
4.32 
(1.88) 
4.15 
(1.80) 
-0.58b 0.566 4.41 
(1.93) 
3.98 
(1.70) 
-1.53b 0.127 
Other maintenance medications at 
discharge, Mean(SD) 
11.76 
(5.43) 
10.06 
(4.91) 
-2.01b 0.046 11.24 
(5.49) 
9.78 
(4.52) 
-1.88b 0.062 
a=Pearson Chi Square value; b=t-test t-value 
 
